Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 Grams
Price: Negotiable
Packaging Details: 1~10 KG Aluminum Foil Bag, 25KG/drum
Delivery Time: 1-3 working day
Payment Terms: L/C, L/C, D/A, D/P, T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Apperance: |
White Powder |
Product Name: |
Molnupiravir (EIDD-2801) |
Molecular Weight: |
329.31 |
Storage: |
Store In A Cool, Dry Place |
Service: |
Worldwide |
Test: |
HPLC |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Apperance: |
White Powder |
Product Name: |
Molnupiravir (EIDD-2801) |
Molecular Weight: |
329.31 |
Storage: |
Store In A Cool, Dry Place |
Service: |
Worldwide |
Test: |
HPLC |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Molnupiravir works by inducing mutations in the viral RNA during replication, leading to an accumulation of errors that inhibit the virus's ability to replicate effectively. This mechanism makes it effective against a wide range of RNA viruses, including influenza viruses, coronaviruses, and others.
| Service | Worldwide |
| Test | HPLC |
| Country Of Origin | China |
| Appearance | White Powder |
| Storage | Store In A Cool, Dry Place |
| Grade | Pharmaceutical Grade |
| Cas | 2349386-89-4 |
| Molecular Formula | C13H19N3O7 |
| Grade Standard | Pharmaceutical Grade |
| Molecular Weight | 329.31 |
| Key Features | Molnupiravir, 2349386-89-4 |
1. COVID-19 Treatment: Molnupiravir has been studied extensively as a potential treatment for COVID-19, caused by the SARS-CoV-2 virus. Clinical trials have evaluated its efficacy and safety in patients with mild to moderate COVID-19 symptoms. Results from some studies suggest that Molnupiravir may reduce the duration of symptoms and decrease the risk of hospitalization when administered early in the course of the disease.
2. Antiviral Therapy: Molnupiravir's mechanism of action involves inhibiting the replication of RNA viruses by introducing errors into their genetic material. This broad-spectrum antiviral activity makes it a candidate for treating various viral infections beyond COVID-19, including influenza, respiratory syncytial virus (RSV), and others. Research is ongoing to explore its effectiveness against different viral pathogens.
3. Preventive Treatment: There is interest in exploring Molnupiravir as a preventive treatment for viral infections, particularly in high-risk populations or during outbreaks. If proven effective, it could be used prophylactically to reduce the spread of viral diseases.
4. Animal Health: Molnupiravir may also find applications in veterinary medicine for treating viral infections in animals. This could include diseases affecting livestock, companion animals, and other species vulnerable to viral pathogens.
